The study enrolled patients with advanced or metastatic NSCLC harboring HER2 mutations, amplification, or overexpression who had progressed after ≥1 prior lines of anticancer therapy. After enrollment, participants received treatment with rezetamab plus pertuzumab until disease progression, intolerable toxicity, withdrawal of consent, or other conditions requiring treatment discontinuation.
Aged 18-75 years
Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) (AJCC 9th edition)
Pathologically documented HER2 mutation, amplification, or overexpression
Received ≥1 prior line of systemic anti-cancer therapy for advanced/metastatic disease
There are untreated or active central nervous system (CNS) tumor metastases
Has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI-CTCAE version 5.0 grade ≤ 1.
Pleural, ascites, or pericardial effusion requiring intervention occurred within 14 days prior to initial administration
Systemic antitumor therapy was performed 4 weeks prior to study initiation
The First Affiliated Hospital of Guangzhou Medical University
Lead sponsor
Maoming People's Hospital
Collaborator
Peking University Shenzhen Hospital
Collaborator